Development of a Genomics-based Multimodal Prediction Model for Post-stroke Vascular Dementia

Inclusion Criteria: 1. Healthy Control Group: * Adults aged 19 years or older. * Able to be age- and sex-matched to the stroke cohort. * No history of stroke, transient ischemic attack (TIA), or other central nervous system disorders. * Cognitive function within the normal range for age and education level based on screening assessments (K-MMSE and K-MoCA). * Able to understand the study procedures and provide written informed consent. 2. Stroke Patient Group: * Adults aged 19 years or older. * First-ever ischemic or hemorrhagic stroke confirmed by CT or MRI. * Enrolled in one of the following strata according to time since stroke onset: Stratum A: 7 days to 3 months after stroke onset. Stratum B: \>3 months to 12 months after stroke onset. Stratum C: \>12 months to 36 months after stroke onset. \- Able to understand the study procedures and provide written informed consent, or consent provided by a legally authorized representative when applicable. Exclusion Criteria: 1. Healthy Control Group: * Current severe psychiatric disorders that may affect cognitive function (e.g., major depression, schizophrenia) or use of related medications. * Strong family history of hereditary cerebrovascular disorders (e.g., CADASIL). * Severe medical illness considered inappropriate for study participation. * Any condition that, in the opinion of the investigator, would make participation unsuitable. 2. Stroke Patient Group: * Impaired ability to provide consent (MMSE \<10) without an accompanying caregiver or legally authorized representative. * History of dementia due to causes other than stroke (e.g., Alzheimer's disease) prior to stroke onset. * History of major neurological disorders affecting cognition prior to stroke onset (e.g., Parkinson's disease, brain tumor, multiple sclerosis). * Severe aphasia or impaired consciousness preventing completion of cognitive assessments. * Current or pre-stroke severe psychiatric disorders that may affect cognitive function (e.g., major depression, schizophrenia) or use of related medications. * Strong family history of hereditary cerebrovascular disorders (e.g., CADASIL). * Contraindication to MRI (e.g., metallic implants) or refusal to provide blood samples for genomic analysis. * Any condition that, in the opinion of the investigator, would make participation unsuitable.